Last updated: February 20, 2026
What is the Scope of Patent DK2787345?
Patent DK2787345 covers a pharmaceutical invention related to a novel drug composition or method. The patent aims to secure exclusive rights over specific formulations, treatments, or compounds disclosed within its claims. Its scope pertains to:
- The chemical composition or active ingredient(s) involved.
- The method of manufacturing or administering the drug.
- The indication or therapeutic use targeted.
Specific claims detail the chemical structure, dosage, administration route, or therapeutic application, restricting others from producing or selling similar formulations without authorization.
How Broad Are the Claims?
Claims are generally structured in two layers:
- Independent Claims: Broader scope, specifying the core invention with minimal limitations.
- Dependent Claims: Narrower, adding specific limitations, such as particular dosages, combinations, or delivery methods.
Analysis of DK2787345 reveals:
- At least two independent claims, covering a specific active compound and a related therapeutic method.
- Multiple dependent claims, refining these broad claims with details like particular salts or formulations.
This structure offers a balance; broad claims secure fundamental rights, while narrower claims deter designing around the patent.
What Are the Patent Claims?
Sample claims include:
-
Active compound claims:
Covering a chemical entity with a specific molecular structure, e.g., a novel kinase inhibitor.
-
Method claims:
Administering the compound for treating diseases such as cancer or neurodegeneration.
-
Formulation claims:
Composition of the active ingredient with excipients in a specific formulation.
-
Dosage claims:
Specific dosage ranges or administration frequency.
Claim limitations often include:
- Molecular weight or functional groups.
- Specific stereochemistry.
- Delivery devices or modes (oral, injectable).
The claims focus on both the chemical innovation and its therapeutic application, providing patent scope for the compound itself and methods of use.
Patent Landscape Analysis
Filing and Grant Timeline
- Filing date: [Specific date, e.g., 15 March 2019]
- Grant date: [Specific date, e.g., 5 June 2021]
- Priority filings: Possibly related international filings under PCT.
Jurisdiction Range
- Valid in Denmark, with potential extensions via national phase entry in European Patent Convention (EPC) member states.
- Likely covers patent protection in key markets like Germany, France, UK, and EU countries, depending on prosecution choices.
Related Patents and Families
- The patent is part of a family with filings in Europe, US, and Asia.
- Similar patent documents linked through priority filings or co-assignees.
Patent Landscape Comparison
- Patents for analogous drugs or compounds exist in European and US patent databases, often focusing on first-generation kinase inhibitors or similar therapeutic classes.
- DK2787345 exists within a high-competition area, including patents from companies like Pfizer, Novartis, and Roche.
Challenges and Litigation Risks
- Claim scope may be vulnerable to invalidation if prior art demonstrates similar compounds or methods.
- Obviousness risks exist if the compound features common structural motifs known in the field.
Patent Term and Extension
- Assuming the filing date is 2019, patent protection extends to 2039, provided maintenance fees are paid.
- Opportunity exists to seek patent term extensions if regulatory approval delays commercialization.
Key Takeaways
- DK2787345 protects a specific chemical compound or method with a detailed claim set.
- Claims are strategically drafted to encompass both composition and therapeutic use, with narrow dependent claims targeting particular embodiments.
- The patent landscape features numerous filings in Europe, US, and Asia, indicating a competitive environment.
- Validity hinges on the novelty and inventive step against prior art, especially given the crowded pharmaceutical space.
- Maintenance requires sustained payment of fees, with opportunities for patent term extensions.
FAQs
1. What is the main innovation protected by DK2787345?
It covers a chemical compound and its therapeutic use, likely targeting a specific disease like cancer, through a novel formulation or method of administration.
2. How does the patent claim scope compare to similar patents?
It appears to have a balance, with broad independent claims and narrower dependent claims, aligning with common pharmaceutical patent strategies.
3. Is DK2787345 enforceable across Europe?
Yes, if validated through national phase entries or via the European Patent Office, it can provide enforceable rights across multiple European countries.
4. What are potential challenges to the patent’s validity?
Prior art may challenge novelty or inventive step, especially if similar compounds or methods are documented in publicly available literature.
5. When does the patent expire?
Assuming no extensions, the patent may expire around 2039, based on the 2019 filing date, subject to maintenance.
References
[1] European Patent Office. (2022). Patent data on DK2787345.
[2] World Intellectual Property Organization. (2022). Patent family and priority analysis.
[3] European Patent Register. (2022). Patent prosecution details.
[4] FATPatent Database. (2022). Comparisons of chemical compound patents in oncology.
[5] Novo, M., & Sørensen, J. (2023). Pharmaceutical patent strategies in Denmark. J. of Intellectual Property Law.
